ChinaBio® Today Articles

Welcome to the ChinaBio® Today store. As a service to our readers, we offer access to individual articles for only $5.00 (USD) each.  Of course, a subscription is only $20/mo, so you may prefer to subscribe.  If so, click on Subscribe in the menu.

Browse


All Products

Viewing 1546 - 1560 of 5996 products
BeiGene Starts Trial of HPK1 Inhibitor, a Novel Immunocology Candidate
$5.00
Available
Alphamab Approved to Start US Trials of PD-L1/CTLA-4 Bispecific
$5.00
Available
Gannex/Ascletis Reports Positive Phase II Data for NASH Treatment
$5.00
Available
CASI Acquires China Rights to a p97 Inhibitor for Cancer in $85 Million Deal
$5.00
Available
WuXi Biologics Out-licenses mAb Panel to Exelixis for Development
$5.00
Available
AlphaBio In-licenses Off-the-Shelf NK/T-Cell Technology for Cancer
$5.00
Available
Taicang's Connect Biopharma Files for $100 Million NASDAQ IPO
$5.00
Available
Wuhan ABconal Acquires Boston mAb Drug Developer Yurogen
$5.00
Available
Kintor OK'd to Start US Trial of Androgen Receptor Antagonist for COVID-19
$5.00
Available
GenSciences Raises $124 Million for New Drug Development
$5.00
Available
Apollomics Starts China Trial of Immunotherapy for AML
$5.00
Available
SciClone IPOs on Hong Kong Exchange, Raising $279 Million
$5.00
Available
Biotheus Completes $100 Million Funding for Biologic Drugs
$5.00
Available
Innoforce and dMed Team Up to Develop/Manufacture Novel Biologics
$5.00
Available
WuXi AppTec Pays $135 Million to Acquire Oxgene, a Gene Therapy CDMO
$5.00
Available